company background image
HCM logo

HUTCHMED (China) AIM:HCM Stock Report

Last Price

UK£2.93

Market Cap

UK£2.5b

7D

3.5%

1Y

33.8%

Updated

14 Jun, 2024

Data

Company Financials +

HCM Stock Overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.

HCM fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance3/6
Financial Health5/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for HCM from our risk checks.

HUTCHMED (China) Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HUTCHMED (China)
Historical stock prices
Current Share PriceUK£2.93
52 Week HighUK£3.53
52 Week LowUK£1.74
Beta0.65
1 Month Change-13.82%
3 Month Change3.53%
1 Year Change33.79%
3 Year Change-29.99%
5 Year Change-36.17%
Change since IPO1,069.66%

Recent News & Updates

Recent updates

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04
We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14
HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01
The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

Dec 18
Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Nov 23
HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

Aug 24
Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

Is HUTCHMED (China) (LON:HCM) A Risky Investment?

May 10
Is HUTCHMED (China) (LON:HCM) A Risky Investment?

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Apr 19
With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Shareholder Returns

HCMGB PharmaceuticalsGB Market
7D3.5%-0.6%-1.5%
1Y33.8%8.7%3.8%

Price Volatility

Is HCM's price volatile compared to industry and market?
HCM volatility
HCM Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement7.4%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.2%
10% least volatile stocks in GB Market2.8%

About the Company

FoundedEmployeesCEOWebsite
20001,988Wei-Guo Suwww.hutch-med.com

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.

HUTCHMED (China) Limited Fundamentals Summary

How do HUTCHMED (China)'s earnings and revenue compare to its market cap?
HCM fundamental statistics
Market capUK£2.50b
Earnings (TTM)UK£79.42m
Revenue (TTM)UK£660.35m

31.5x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HCM income statement (TTM)
RevenueUS$838.00m
Cost of RevenueUS$686.45m
Gross ProfitUS$151.55m
Other ExpensesUS$50.77m
EarningsUS$100.78m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.12
Gross Margin18.08%
Net Profit Margin12.03%
Debt/Equity Ratio10.7%

How did HCM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.